Prime Medicine posts corporate deck outlining prime editing pipeline focus on Wilson disease, AATD
PUBT · 2d ago
Share
Listen to the news
- Prime Medicine outlined a near-term push to advance prime-editing programs in Wilson disease and alpha-1 antitrypsin deficiency.
- Targeted PM577 IND and/or CTA filing in H1 2026, followed by Phase 1 start; initial clinical data expected in 2027.
- Planned PM647 IND and/or CTA filing mid-2026, followed by Phase 1 start; initial clinical data expected in 2027.
- CGD program PM359 positioned toward a BLA filing, with a commercial launch targeted for 2027+.
- Strategy includes additional partnerships, expansion beyond liver, with in vivo cystic fibrosis proof-of-concept data planned in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved